Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Merger or Acquisition (March 2026)
6 slides from Royalty Pharma's merger presentation, March 2026
Slide 1: Royalty acquisition
royalty acquisition March 2026
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete o
Slide 3: Royalty funding agreement: Ziihera for HER2+ gastric & biliary tract cancer
3 Royalty funding agreement: Ziihera for HER2+ gastric & biliary tract cancer 1 2 3 Addressing high unmet need in Clinical results position Ziihera to Multi-blockbuster sales potential gastric and biliary tract cancer become standard of care drives attractive returns Jazz and BeOne’s Ziihera (HER2 I
Slide 4: Ziihera royalty acquisition overview
4 Ziihera royalty acquisition overview Transaction overview Royalty terms Ziihera reported and consensus sales(3) ($ in billions) $2.6 Transaction terms Royalty rate $2.5 • Acquired 30% of existing royalty on Ziihera(1) • Upward tiering low- to mid-single digits $2.3 • $250m upfront payment to Zymew
Slide 5: Gastric cancer results position Ziihera to become standard of care
5 Gastric cancer results position Ziihera to become standard of care Median overall survival(1) Median progression free survival(1) Median duration of response(1) (in months) (in months) (in months) 26.4m 12.4m 12.4m (HR = 0.72) 24.4m (HR = 0.63) (HR = 0.65) (immature at analysis) 20.7m 10.0m 20.0m
Slide 6: Multi-blockbuster commercial opportunity underpinned by GEA
6 Multi-blockbuster commercial opportunity underpinned by GEA Gastroesophageal Biliary Tract Breast & other Adenocarcinoma Cancer HER2 cancers (annual patients) $2b+ peak (~63,000 HER2+ cases annually in U.S., EU, (~12,000 HER2+ cases annually in U.S., EU, (~150,000 HER2+ breast cancer cases annuall